eShop is a platform for people with diabetes to directly purchase Dario & get support, knowledge and tools to manage their diabetes personally and thrive
CAESAREA, Israel, May 7, 2015 /PRNewswire/ — LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today reported it has opened its first ecommerce store for the Dario Smart meter and Dario accessories. The eShop serves the Israeli market, where the Dario Management Solution was launched in July 2014 following approval from the Israeli Ministry of Health. The Dario has received wide commendations and endorsements from both the medical community and the population of patients in Israel. The shop serves as an excellent channel for LabStyle to sell to people with diabetes and engage with them directly.
Watch: https://youtu.be/OFQsS7Orqiw
The eShop offers a platform for people with diabetes to directly purchase the Dario and get the support, knowledge and tools to manage their diabetes personally using their mobile devices. Although LabStyle is seeking reimbursement status in Israel currently Dario is not covered through the health insurance system and therefore all patients are currently buying the Dario smart meter out of pocket.
As LabStyle’s first eShop, this will serve as an ecommerce model for LabStyle Innovations, as it plans to open ecommerce sites to serve other geographic markets where diabetes is prevalent and there is a need for a complete diabetes management solution.
“As more and more emphasis is being placed on the need for improving patient compliance and self-management, it is important that people are able to find a comprehensive management solution so easily online to help them thrive while living with diabetes,” said Erez Raphael, LabStyle’s President and Chief Executive Officer. “The Dario smart meter delivers just what patients are looking for in an intuitive and easy to use tech-driven solution. . We look forward to capturing what we believe is an immense opportunity for Dario in developing this online direct sales approach in the other targeted markets.”
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB:DRIO) develops and commercializes patented technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle’s flagship product is the Dario™ Diabetes Management Solution. Dario™ empowers people with diabetes to take charge of their health with the right tools, insights, and support in their pocket. With access to both real-time and historical blood glucose data, Dario™ is designed to spot patterns, recommend the right treatments and support behavior change efforts. Dario™ is a platform that combines an all-in-one, blood glucose meter, smart phone application (iOS & Android), website application and treatment tools to support more proactive and better informed decisions by patients, doctors and healthcare systems. The stylish and compact self-monitoring system combines a lancet to obtain a blood sample, a proprietary disposable test strip cartridge and a smartphone-driven glucose meter. LabStyle Innovations is led by an experienced management team with vast software, medical device and technology experience and guided by a world class board of directors and scientific advisory board. For more information: www.myDario.com and http://myDario.investorroom.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the “Company”) related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Contacts:
Press and Investor Relations
Brenda Zeitlin
LabStyle Innovations
1 800 896 9062
Brenda@mydario.com
Video – http://youtu.be/OFQsS7Orqiw